AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
Key Highlights
- ➤RINVOQ (ABBV) F-VASI 75 reached 55.1% and 47.4% at week 76
- ➤RINVOQ (ABBV) T-VASI 50 reached 42.5% and 40.1% at week 76
- ➤RINVOQ plus NB-UVB produced numerically higher repigmentation responses than RINVOQ alone
- ➤U.S. FDA review continues for RINVOQ treatment of non-segmental vitiligo
Expert Statements
Kori Wallace, Vice president, global head of immunology clinical development, AbbVie
“Vitiligo is a chronic, unpredictable disease that can affect skin across the body, underscoring the need for systemic treatment options that go beyond addressing individual areas.”
Kori Wallace, Vice president, global head of immunology clinical development, AbbVie
“These late-breaking data support that RINVOQ can provide meaningful long-term repigmentation for patients with vitiligo and provide an early foundation for further research into its combination with NB-UVB phototherapy.”
Julien Seneschal, Professor of dermatology, National Reference Center for Rare Skin Diseases, University of Bordeaux, France
“These findings are important for physicians treating people with vitiligo because they extend our understanding of repigmentation with continued RINVOQ treatment and provide the first data on combining NB-UVB with an approved systemic JAK inhibitor.”
Julien Seneschal, Professor of dermatology, National Reference Center for Rare Skin Diseases, University of Bordeaux, France
“This research opens an important path for further investigation into how combination approaches could evolve to support patient care in non-segmental vitiligo.”
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo PR Newswire
* RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic therapy * Phase 3 Viti-Up-1 and Viti-Up-2 studies show that among patients continuing RINVOQ, the proportions who achieved facial (F-VASI 75) and total body (T-VASI 50) repigmentation continued to increase through week 76 * Findings from a phototherapy substudy show numerically higher responses with RINVOQ in combination with narrowband ultraviolet B (NB-UVB) phototherapy than with RINVOQ alone * Data are being shared in a late-breaking oral presentation at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria NORTH CHICAGO, Ill., Oct. 1, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ(®) (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial and total body repigmentation through week 76.
Get started
Create a free account to read the full story.